万春医药 BYSI 深 沪
已收盘 07-02 16:00:00 美东时间
1.87
+0.020
+1.08%
华盛通- 最 高1.92
- 今 开1.88
- 成交量 3.62万股
- 最 低 1.835
- 昨 收 1.85
- 总市值 7.69万
- 52周最高 2.44
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 1.175
- 委 比 79.53%
- 总股本 4.11万
- 历史最高 48.49
- 量 比 0.80
- 振 幅 4.59%
- 历史最低 0.542
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BeyondSpring Appoints Min Qiu As CEO, Effective July 1
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully
06-04 19:10
Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit:
06-02 19:15
BeyondSpring GAAP EPS of -$0.06
BeyondSpring press release (BYSI): Q1 GAAP EPS of -$0.06. Cash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026 More on BeyondSpring Historical earnings data for Be...
05-13 19:29
BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
05-13 19:23
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported financial results for Q1 2026 and highlighted advancements in its pipeline. Plinabulin demonstrated potential as a backbone agent for ADC-based therapies, improving efficacy and tolerability. SEED's ST-01156, a molecular glue degrader, advanced into clinical development. The company's R&D expenses increased slightly, while G&A expenses decreased. Net loss was $2.4 million, and cash reserves were $7.9 million. BeyondSpri...
05-13 11:00
万春医药（BYSI.US）4月27日收盘报1.56美元/股，跌8.5%
截至2026年4月27日（美国东部时间）收盘，万春医药(BYSI.US)报收于1.56美元/股，下跌8.5%，成交量1.84万股。
04-28 06:20
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted
BeyondSpring publishes IO360 Summit presentation on plinabulin; PD-1/L1 resistance highlighted BeyondSpring published a presentation titled “Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin.” The presentation was posted as part of the 2026 IO360 Summit materials. Document URL: h
03-26 21:37
